Filtered By:
Drug: Diovan

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 78 results found since Jan 2013.

Predictors of Stroke in Patients With Impaired Glucose Tolerance: Results From the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Trial Brief Reports
Conclusions— The most powerful predictors of stroke in patients with impaired glucose tolerance included a combination of established risk factors and novel variables, such as previous venous thromboembolism and elevated waist circumference, allowing moderately effective identification of high-risk individuals.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Preiss, D., Giles, T. D., Thomas, L. E., Sun, J.-L., Haffner, S. M., Holman, R. R., Standl, E., Mazzone, T., Rutten, G. E., Tognoni, G., Chiang, F.-T., McMurray, J. J. V., Califf, R. M. Tags: Cerebrovascular disease/stroke, Risk Factors, Glucose intolerance Brief Reports Source Type: research

Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open‐label, blinded–end‐point trial
ConclusionsEarly reduction of BP with valsartan did not reduce death or dependency and major vascular events at 90 days, but increased the risk of END.
Source: International Journal of Stroke - January 12, 2015 Category: Neurology Authors: Mi Sun Oh, Kyung‐Ho Yu, Keun‐Sik Hong, Dong‐Wha Kang, Jong‐Moo Park, Hee‐Joon Bae, Jaseong Koo, Juneyoung Lee, Byung‐Chul Lee, Tags: Research Source Type: research

Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats.
Abstract The effects of levosimendan on cerebrovascular lesions and mortality were investigated in models of primary and secondary stroke. We aimed to determine whether the effects of levosimendan are comparable to and/or cumulative with those of valsartan, and to investigate whether levosimendan-induced vasodilation has a role in its effects on stroke. In a primary stroke Dahl/Rapp rat model, mortality rates were 70% and 5% for vehicle and levosimendan, respectively. Both stroke incidence (85% vs. 10%, P<0.001) and stroke-associated behavioral deficits (7-point neuroscore: 4.59 vs. 5.96, P<0.001) were worse...
Source: European Journal of Pharmacology - January 29, 2015 Category: Drugs & Pharmacology Authors: Levijoki J, Kivikko M, Pollesello P, Sallinen J, Hyttilä-Hopponen M, Kuoppamäki M, Haasio K, Gröhn O, Miettinen R, Puoliväli J, Tähtivaara L, Yrjänheikki J, Haapalinna A Tags: Eur J Pharmacol Source Type: research

Effectiveness and safety of valsartan/amlodipine in hypertensive patients with stroke: China Status II subanalysis
Abstract: High blood pressure (BP) is a major risk factor associated with stroke in China. This is a subanalysis of patients from the China Status II study, aimed to evaluate the effectiveness and safety of valsartan/amlodipine (Val/Aml) single-pill combination (SPC) in hypertensive patients with different stroke subtypes (hemorrhagic, ischemic, or mixed). China Status II was a multicenter, postmarketing, prospective observational study in hypertensive patients uncontrolled on monotherapy. The study was an 8-week open-label treatment period with 2 4-week follow-ups. Change in BP from baseline to weeks 4 and 8, BP control ...
Source: Medicine - June 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat
Conclusion: The dual angiotensin II type 1 receptor/neutroendopeptidase inhibition significantly increased atrial natriuretic peptide level and reduced BP. Complete prevention of stroke was achieved in this model. The ability of sacubitril/valsartan to reduce organ damage progression was superior to that of valsartan alone. ARNi may represent a highly effective therapeutic agent to protect from target organ damage development in hypertension.
Source: Journal of Hypertension - September 1, 2018 Category: Cardiology Tags: ORIGINAL PAPERS: Treatment Source Type: research

A Cost-Utility Analysis of Calcium Channel Blockers (Ccbs) Compared with Angiotensin II Receptor Blockers (Arbs) In Preventing Stroke And Myocardial Infarction Among Hypertension Patients In The Taiwan
Hypertension is a major risk factor for stroke and myocardial infarction (MI), which imposes a substantial burden on patients, caregivers, and society. Despite the high financial burden, limited studies have examined the cost-effectiveness of hypertension treatments in Taiwan. This cost utility analysis was conducted to determine the costs and quality-adjusted life years (QALYs) associated with amlodipine (CCB) and valsartan (ARB) in preventing stroke and MI among Taiwanese hypertension patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: C.H. Fang, K.Y. Lin, Y.C. Huang, L. Liu Source Type: research

Brain-targeted delivery of Valsartan using solid lipid nanoparticles labeled with Rhodamine B; a promising technique for mitigating the negative effects of stroke
Drug Deliv. 2023 Dec;30(1):2179127. doi: 10.1080/10717544.2023.2179127.ABSTRACTThe brain is a vital organ that is protected from the general circulation and is distinguished by the presence of a relatively impermeable blood brain barrier (BBB). Blood brain barrier prevents the entry of foreign molecules. The current research aims to transport valsartan (Val) across BBB utilizing solid lipid nanoparticles (SLNs) approach to mitigate the adverse effects of stroke. Using a 32-factorial design, we could investigate and optimize the effect of several variables in order to improve brain permeability of valsartan in a target-spec...
Source: Drug Delivery - February 16, 2023 Category: Drugs & Pharmacology Authors: Shereen A Sabry Amal M Abd El Razek Mohamed Nabil Shaimaa M Khedr Hanan M El-Nahas Noura G Eissa Source Type: research

A Cost Utility Analysis of Amlodipine Compared with Angiotensin II Receptor Blockers in Preventing Stroke and Myocardial Infarction Among Hypertension Patients in the Philippines
Hypertension represents a major health problem, affecting more than 21% of adults in the Philippines. Amlodipine, a calcium channel blocker, is considered to have better tolerance and effectiveness than other classes of antihypertensive treatments. Limited studies have examined the cost-effectiveness of Amlodipine in the Philippines. The purpose of this study was to compare the costs and effectiveness associated with Amlodipine and Angiotensin II Receptor Blockers (Valsartan) in preventing stroke and myocardial infarction (MI) among Filipino hypertension patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: G Encelan-Brizuela, K.Y. Lin, L. Liu Source Type: research

Antibiotic use linked to increased risk of heart attack and stroke in women
Risk is greatest for older women who take antibiotics for more than two months Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Cardio risk raised in people using long-acting bronchodilators Recurrent stroke more likely at very low BP Rising use of antithrombotics linked to subdural haematoma Adding insulin to metformin linked to higher mortality
Source: OnMedica Latest News - May 27, 2019 Category: UK Health Source Type: news

Subcutaneous implanted cardioverter ‐defibrillator in ventricular noncompaction, coronary artery disease and stroke
This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - July 13, 2021 Category: Cardiology Authors: Claudia St öllberger, Edmund Gatterer, Matthias Hasun, Zsuzsanna Arnold, Josef Finsterer Tags: CASE REPORT Source Type: research

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
ConclusionsStroke volume index is positively associated with complete titration of sacubitril/valsartan. Patients with low SVi are more prone to experience hypotension during titration
Source: ESC Heart Failure - March 23, 2022 Category: Cardiology Authors: Paolo Tolomeo, Ottavio Zucchetti, Emanuele D'Aniello, Noemi Punzo, Federico Marchini, Luca Di Ienno, Elisabetta Tonet, Rita Pavasini, Claudio Rapezzi, Gianluca Campo, Matteo Serenelli Tags: Short Communication Source Type: research

No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
In conclusion, patients in BP strata ≥ 150/90 mmHg, but not patients in BP strata < 130/70 mmHg, were at increased risk for adverse outcomes in this hypertensive, high-risk population. Although benefit in preventing MI in relation to preventing stroke levels off for the lowest BPs, these data provide no support for a J-curve in the treatment of high-risk hypertensive patients . The increase in the ratio of MI to stroke with lower DBP indicates target organ heterogeneity in that the optimal on-treatment DBP for cerebroprotection is below that for cardioprotection. PMID: 26511535 [PubMed - in process]
Source: Blood Pressure - February 14, 2016 Category: Hematology Tags: Blood Press Source Type: research